NCT07374965

A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A

A Prospective, Non-interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 20 (actual)
• Sponsor: Yuvell · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The goal of this observational study is to learn about the safety, tolerability, and effectiveness of Letibotulinumtoxin A for the holistic treatment of the upper face in adults under 75 years old with moderate to severe upper facial lines, including glabellar lines, forehead lines, and lateral canthal lines. The main questions it aims to answer are: * Does Letibotulinumtoxin A safely and effectively reduce the severity of glabellar lines, forehead lines, and lateral canthal lines in adults under 75? * How well is the treatment tolerated in everyday clinical practice? * What is the patient satisfaction with holistic upper face treatment using Letibotulinumtoxin A? Participants will: * receive Letibotulinumtoxin A injections in the upper face, including glabellar lines, forehead lines, and lateral canthal lines. * be observed and followed up to assess the severity of wrinkles, duration of effect, and patient satisfaction. * report any adverse effects experienced during or after treatment.

Conditions

• Glabellar Lines
• Forehead Lines
• Crow's Feet
• Canthal Lines

Interventions

Type	Name	Description
DRUG	Letybo®	Drug is used as part of routine clinical care. This observational study does not assign or modify treatment; it observes outcomes associated with drug use.

Timeline

• Start date: 2024-01-29
• Primary completion: 2024-05-16
• Completion: 2024-09-09
• First posted: 2026-01-29
• Last updated: 2026-01-29

Locations

1 site across 1 country: Austria